Pankhuri Wanjari

902 total citations
35 papers, 467 citations indexed

About

Pankhuri Wanjari is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Pankhuri Wanjari has authored 35 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Pankhuri Wanjari's work include Renal cell carcinoma treatment (10 papers), Genetic factors in colorectal cancer (7 papers) and Ovarian cancer diagnosis and treatment (7 papers). Pankhuri Wanjari is often cited by papers focused on Renal cell carcinoma treatment (10 papers), Genetic factors in colorectal cancer (7 papers) and Ovarian cancer diagnosis and treatment (7 papers). Pankhuri Wanjari collaborates with scholars based in United States, Canada and United Kingdom. Pankhuri Wanjari's co-authors include Tatjana Antic, Jeremy P. Segal, Melissa Y. Tjota, Megan Parilla, Jennifer A. Bennett, Lauren L. Ritterhouse, Esther Oliva, Jeremy Segal, Heather Chen and Sabah Kadri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Pankhuri Wanjari

31 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pankhuri Wanjari United States 15 243 172 94 71 70 35 467
Laveta Stewart United States 4 344 1.4× 350 2.0× 56 0.6× 69 1.0× 104 1.5× 4 528
Khaleel I. Al‐Obaidy United States 13 296 1.2× 227 1.3× 35 0.4× 28 0.4× 95 1.4× 48 472
Qun-Li Shi China 18 265 1.1× 273 1.6× 115 1.2× 111 1.6× 122 1.7× 41 584
Anna Felisiak-Gołąbek Poland 14 206 0.8× 156 0.9× 23 0.2× 126 1.8× 90 1.3× 20 544
Kathryn E. Pearce United States 13 187 0.8× 258 1.5× 16 0.2× 53 0.7× 106 1.5× 31 512
Ülkü Öner Türkiye 13 201 0.8× 86 0.5× 29 0.3× 26 0.4× 67 1.0× 17 411
John K. Schoolmeester United States 13 221 0.9× 115 0.7× 106 1.1× 16 0.2× 28 0.4× 23 587
Danuta Skomra Poland 12 71 0.3× 112 0.7× 23 0.2× 72 1.0× 36 0.5× 45 344
J. Mazurka Canada 10 85 0.3× 167 1.0× 25 0.3× 68 1.0× 45 0.6× 15 488
Amanda Hemmerich United States 10 126 0.5× 124 0.7× 13 0.1× 122 1.7× 72 1.0× 36 421

Countries citing papers authored by Pankhuri Wanjari

Since Specialization
Citations

This map shows the geographic impact of Pankhuri Wanjari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pankhuri Wanjari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pankhuri Wanjari more than expected).

Fields of papers citing papers by Pankhuri Wanjari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pankhuri Wanjari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pankhuri Wanjari. The network helps show where Pankhuri Wanjari may publish in the future.

Co-authorship network of co-authors of Pankhuri Wanjari

This figure shows the co-authorship network connecting the top 25 collaborators of Pankhuri Wanjari. A scholar is included among the top collaborators of Pankhuri Wanjari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pankhuri Wanjari. Pankhuri Wanjari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Wang, Peng, Pankhuri Wanjari, James M. Paik, et al.. (2025). Renal Tumorigenesis via RAS/RAF/MAPK Pathway Alterations Beyond Papillary Renal Neoplasm With Reverse Polarity. The American Journal of Surgical Pathology. 49(12). 1266–1278. 2 indexed citations
3.
4.
Tjota, Melissa Y., et al.. (2025). A Deeper Dive into POLE-Mutated Endometrial Carcinomas. The American Journal of Surgical Pathology. 50(3). 301–312.
5.
Chen, Heather, Pankhuri Wanjari, Peng Wang, et al.. (2024). Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization. Cancer Medicine. 13(1). e6873–e6873. 6 indexed citations
6.
Devins, Kyle M., Zehra Ordulu, Sabrina Croce, et al.. (2024). Uterine Inflammatory Myofibroblastic Tumors. The American Journal of Surgical Pathology. 48(7). 813–824. 4 indexed citations
7.
Kraft, Ira L., Caner Saygin, Pankhuri Wanjari, et al.. (2023). Sequential tumor molecular profiling identifies likely germline variants. Genetics in Medicine. 26(3). 101037–101037. 3 indexed citations
9.
Wang, Peng, Heather Smith, Carrie Fitzpatrick, et al.. (2023). Clinicopathologic Analysis and Molecular Profiling of Ovarian Steroid Cell Tumors. The American Journal of Surgical Pathology. 47(12). 1398–1408. 2 indexed citations
10.
Tjota, Melissa Y., et al.. (2022). TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Human Pathology. 134. 124–133. 9 indexed citations
11.
Petras, Kristin, Kelly Arndt, Pankhuri Wanjari, et al.. (2022). Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation. 43(7). 950–962. 17 indexed citations
12.
Al‐Obaidy, Khaleel I., Julia A. Bridge, Liang Cheng, et al.. (2021). EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. Modern Pathology. 34(10). 1921–1934. 34 indexed citations
13.
Bennett, Jennifer A., Zehra Ordulu, Robert H. Young, et al.. (2021). Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations. Modern Pathology. 34(9). 1750–1762. 24 indexed citations
14.
Kao, Yu‐Chien, Jennifer A. Bennett, Albert J.H. Suurmeijer, et al.. (2021). Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts. Modern Pathology. 34(6). 1203–1212. 30 indexed citations
15.
Somasegar, Sahana, et al.. (2021). Phyllodes tumor of the vulva: A case report and literature review highlighting a novel manifestation of Cowden syndrome. Gynecologic Oncology Reports. 36. 100752–100752.
16.
Parilla, Megan, et al.. (2020). A Tale of 2 Morphologies: Diagnostic Pitfalls in TFEB-Associated Renal Cell Carcinomas, Including a Novel NEAT1-TFEB Fusion. International Journal of Surgical Pathology. 29(1). 21–29. 5 indexed citations
17.
Tjota, Melissa Y., Heather Chen, Megan Parilla, et al.. (2020). Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous. The American Journal of Surgical Pathology. 44(7). 943–954. 62 indexed citations
18.
Ritterhouse, Lauren L., Megan Parilla, Chao Jie Zhen, et al.. (2019). Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. Molecular Diagnosis & Therapy. 23(6). 791–802. 13 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026